{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:40:05Z","timestamp":1793047205435,"version":"4.5.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Activated PI3K-kinase Delta Syndrome (APDS) is an autosomal-dominant primary immunodeficiency (PID) caused by the constitutive activation of the PI3K\u03b4 kinase. The consequent hyperactivation of the PI3K-Akt-mTOR pathway leads to an impaired T- and B-cells differentiation and function, causing progressive lymphopenia, hypogammaglobulinemia and hyper IgM. Patients with APDS show recurrent sinopulmonary and chronic herpes virus infections, immune dysregulation manifestations, including cytopenia, arthritis, inflammatory enteropathy, and a predisposition to persistent non-neoplastic splenomegaly\/lymphoproliferation and lymphoma. The recurrence of the lymphoproliferative disorder and the difficulties in the proper definition of malignancy on histological examination represents the main challenge in the clinical management of APDS patients, since a prompt and correct diagnosis is needed to avoid major complications. Targeted therapies with PI3K\u03b4-Akt-mTOR pathway pharmacologic inhibitors (i.e., Rapamycin, Theophylline, PI3K inhibitors) represent a good therapeutic strategy. They can also be used as bridge therapies when HSCT is required in order to control refractory symptoms. Indeed, treated patients showed a good tolerance, improved immunologic phenotype and reduced incidence\/severity of immune dysregulation manifestations. Here, we describe our experience in the management of four patients, one male affected with APDS1 (P1) and the other three, a male and two females, with APDS2 (P2, P3, P4) presenting with chronic EBV replication, recurrent episodes of immune dysregulation manifestations and lymphomas. These cases highlighted the importance of a tailored and close follow-up, including serial endoscopic and lymph nodes biopsies control to detect a prompt and correct diagnosis and offer the best therapeutic strategy.<\/jats:p>","DOI":"10.3389\/fped.2021.703853","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T15:58:49Z","timestamp":1630943929000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up"],"prefix":"10.3389","volume":"9","author":[{"given":"Beatrice","family":"Rivalta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Amodio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Milito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chiriaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Di Cesare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Giancotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Santilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pacillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Cifaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giovanna","family":"Desimio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Quinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"De Vito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gigliola","family":"Di Matteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Finocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Trizzino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Tommasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Cancrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage","volume":"342","author":"Angulo","year":"2013","journal-title":"Science."},{"key":"B2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1172\/JCI75746","article-title":"A human immunodeficiency caused by mutations in the PIK3R1 gene","volume":"124","author":"Deau","year":"2014","journal-title":"J Clin Invest."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1084\/jem.20141759","article-title":"Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K","volume":"211","author":"Lucas","year":"2014","journal-title":"J Exp Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri.2016.93","article-title":"PI3K\u03b4 and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat Rev Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.jaci.2019.03.017","article-title":"PI3K pathway defects leading to immunodeficiency and immune dysregulation","volume":"143","author":"Nunes-Santos","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jaci.2018.04.030","article-title":"Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity","volume":"143","author":"Edwards","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.00446","article-title":"Exhaustion of the CD8+ T cell compartment in patients with mutations in phosphoinositide 3-kinase delta","volume":"9","author":"Wentink","year":"2018","journal-title":"Front Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.clim.2017.01.004","article-title":"Genetic defects in PI3K\u03b4 affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections","volume":"176","author":"Wentink","year":"2017","journal-title":"Clin Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.3389\/fimmu.2017.02005","article-title":"Epstein-Barr virus susceptibility in Activated PI3K\u03b4 Syndrome (APDS) immunodeficiency","volume":"8","author":"Carpier","year":"2018","journal-title":"Front Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.01758","article-title":"Genetic defects in phosphoinositide 3-kinase \u03b4 influence CD8+ T cell survival, differentiation, and function","volume":"9","author":"Cannons","year":"2018","journal-title":"Front Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/imr.12790","article-title":"T and B-cell signaling in activated PI3K delta syndrome: From immunodeficiency to autoimmunity","author":"Preite","year":"2019","journal-title":"Immunol Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.jaci.2017.11.042","article-title":"Mutations in PI3K110\u03b4 cause impaired natural killer cell function partially rescued by rapamycin treatment","volume":"142","author":"Ruiz-Garc\u00eda","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clim.2015.12.008","article-title":"The case of an APDS patient: Defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment","volume":"178","author":"Chiriaco","year":"2017","journal-title":"Clin Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase \u03b4 syndrome: A large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","article-title":"Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase \u03b4 syndrome 2: A cohort study","volume":"138","author":"Elkaim","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fped.2021.652405","article-title":"Activated PI3Kinase Delta Syndrome\u2014A Multifaceted Disease","volume":"9","author":"Thouenon","year":"2021","journal-title":"Front Pediatr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00753","article-title":"Case study: Mechanism for increased follicular helper T cell development in activated PI3K delta syndrome","volume":"10","author":"Thauland","year":"2019","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3389\/fimmu.2012.00244","article-title":"Does the PI3K pathway promote or antagonize regulatory T cell development and function?","volume":"3","author":"Soond","year":"2012","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/JLB.2MIR0817-349R","article-title":"The PI3K\/AKT signaling pathway in regulatory T-cell development, stability, and function","volume":"103","author":"Pompura","year":"2018","journal-title":"J Leukoc Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jaci.2019.01.033","article-title":"Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4+ T cells","volume":"144","author":"Bier","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41590-018-0182-3","article-title":"Hyperactivated PI3K\u03b4 promotes self and commensal reactivity at the expense of optimal humoral immunity","volume":"19","author":"Preite","year":"2018","journal-title":"Nat Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1084\/jem.20180010","article-title":"Germline-activating mutations in PIK3CD compromise B cell development and function","volume":"215","author":"Avery","year":"2018","journal-title":"J Exp Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.3389\/fimmu.2018.02172","article-title":"Class-Switch Recombination (CSR)\/Hyper-IgM (HIGM) Syndromes and Phosphoinositide 3-Kinase (PI3K) Defects","volume":"9","author":"Jhamnani","year":"2018","journal-title":"Front Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1084\/jem.20180617","article-title":"Activated PIK3CD drives innate B cell expansion yet limits B cell-intrinsic immune responses","volume":"215","author":"Wray-Dutra","year":"2018","journal-title":"J Exp Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2021.04.010","article-title":"Infections in activated PI3K delta syndrome (APDS)","volume":"72","author":"Brodsky","year":"2021","journal-title":"Curr Opin Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood.2019002072","article-title":"Increased activation of PI3 kinase-\u03b4 predisposes to B-cell lymphoma","volume":"135","author":"Durandy","year":"2020","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.00338","article-title":"Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase \u03b4 Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase \u03b4 Syndrome Registry","volume":"9","author":"Maccari","year":"2018","journal-title":"Front Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.3390\/jcm9103335","article-title":"Activated Phosphoinositide 3-Kinase Delta Syndrome 1: Clinical and Immunological Data from an Italian Cohort of Patients","volume":"9","author":"Tessarin","year":"2020","journal-title":"J Clin Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2017.06.009","article-title":"Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders","volume":"141","author":"Hauck","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1182\/blood.2019000923","article-title":"Immune dysregulation in patients with RAG deficiency and other forms of combined immune deficiency","volume":"135","author":"Delmonte","year":"2020","journal-title":"Blood."},{"key":"B32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/imr.12791","article-title":"Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases","volume":"291","author":"Latour","year":"2019","journal-title":"Immunol Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1084\/jem.20161846","article-title":"Human immunity against EBV\u2014lessons from the clinic","volume":"214","author":"Tangye","year":"2017","journal-title":"J Exp Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/bjh.12422","article-title":"Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases","volume":"162","author":"Parvaneh","year":"2013","journal-title":"Br J Haematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/blood.2019000928","article-title":"Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection","volume":"135","author":"Tangye","year":"2020","journal-title":"Blood."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.00237","article-title":"Herpesviruses in the activated phosphatidylinositol-3-kinase-\u03b4 syndrome","volume":"9","author":"Cohen","year":"2018","journal-title":"Front Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.5501\/wjv.v1.i6.154","article-title":"Roles of the PI3K\/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications","volume":"1","author":"Chen","year":"2012","journal-title":"World J Virol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jaci.2014.02.020","article-title":"Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase \u03b4 syndrome","volume":"134","author":"Kracker","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/MPH.0000000000001487","article-title":"A Rare Case of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Presenting with Hemophagocytosis Complicated with Hodgkin Lymphoma","volume":"42","author":"Cansever","year":"2020","journal-title":"J Pediatr Hematol Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ped4.12101","article-title":"Clinical and genetic analysis of immunodeficiency-related diseases associated with PIK3CD mutations","volume":"2","author":"Zhang","year":"2018","journal-title":"Pediatr Investig."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2020.108543","article-title":"Paediatric MAS\/HLH caused by a novel monoallelic activating mutation in p110\u03b4","volume":"219","author":"Lougaris","year":"2020","journal-title":"Clin Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fped.2018.00402","article-title":"Evaluation of lymphoproliferative disease and increased risk of lymphoma in activated phosphoinositide 3 Kinase delta syndrome: A case report with discussion","volume":"6","author":"Pham","year":"2018","journal-title":"Front Pediatr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.jaip.2018.02.029","article-title":"Theophylline as a precision therapy in a young girl with PIK3R1 immunodeficiency. J Allergy Clin Immunol Pract","volume":"6","author":"Valencic","year":"2018","journal-title":"Am Acad Allergy Asthma Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \u201cactivated PI3K\u03b4 syndrome\u201d \u2013targeted therapy with the PI3K\u03b4 inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.02043","article-title":"The Treatment of Activated PI3K\u03b4 Syndrome","volume":"9","author":"Coulter","year":"2018","journal-title":"Front Immunol."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000326","article-title":"Seletalisib for Activated PI3K\u03b4 Syndromes: Open-Label Phase 1b and Extension Studies","author":"Diaz","year":"2020","journal-title":"J Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.00369","article-title":"Activated PI3 kinase delta syndrome: From genetics to therapy","volume":"9","author":"Michalovich","year":"2018","journal-title":"Front Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.antiviral.2012.09.021","article-title":"Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus","volume":"96","author":"Goswami","year":"2012","journal-title":"Antiviral Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaci.2018.04.032","article-title":"Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase \u03b4 syndrome type 1","volume":"143","author":"Okano","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jaci.2016.09.040","article-title":"Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome","volume":"139","author":"Nademi","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaci.2018.08.039","article-title":"Hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase \u03b4 syndrome: Who, when, and how?","volume":"143","author":"Notarangelo","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.079","article-title":"International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome","author":"Dimitrova","year":"2021","journal-title":"J Allergy Clin Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2249.2010.04206.x","article-title":"Reference values for B cell subpopulations from infancy to adulthood","volume":"162","author":"Morbach","year":"2010","journal-title":"Clin Exp Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/cyto.b.21728","article-title":"Extended immunophenotyping reference values in a healthy pediatric population","volume":"96","author":"Garcia-Prat","year":"2019","journal-title":"Cytom Part B Clin Cytom."},{"key":"B55","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1365-3083.2012.02671.x","article-title":"Paediatric Reference Values for the Peripheral T cell Compartment","volume":"75","author":"Schatorj\u00e9","year":"2012","journal-title":"Scand J Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jpeds.2005.10.033","article-title":"A novel form of non-X-linked hyperigm associated with growth and pubertal disturbances and with lymphoma development","volume":"148","author":"Moschese","year":"2006","journal-title":"J Pediatr."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3389\/fimmu.2017.01194","article-title":"Natural killer cell response to chemotherapy-stressed cancer cells: Role in tumor immunosurveillance","volume":"8","author":"Zingoni","year":"2017","journal-title":"Front Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00077","article-title":"Disseminated and congential toxoplasmosis in a mother and child with activated P13-Kinase \u03b4 syndrome type 2 (APDS2): Case re port and a literature review of toxoplasma infections in primary immunodeficiencies","volume":"10","author":"Karanovic","year":"2019","journal-title":"Front Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature21406","article-title":"Phosphatidylinositol 3-kinase \u03b4 blockade increases genomic instability in B cells","volume":"542","author":"Compagno","year":"2017","journal-title":"Nature."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.703853\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T15:58:50Z","timestamp":1630943930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.703853\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":59,"alternative-id":["10.3389\/fped.2021.703853"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.703853","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,27]]},"article-number":"703853"}}